Skip to main content

Table 1 Patient and transplant characteristics

From: Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

patient characteristics

 gender (f/m)

27 / 21

 age (yrs)

49 [45–57]

 body weight (kg)

68 [59–78]

 BMIa (kg/m2)

22.9 [21.2–26.1]

 # of transplantation (n)

  1st

16

  2nd

20

  3rd or more

12

 PRAb max. (%)

43 [22–76]

transplant characteristics

 DD / LDc

39 / 9

 donor age (yrs.)

52 [44–58]

 MM HLA class I (A + B)d (n)

2 [2–3]

 MM HLA class II (DR + DQ)d (n)

2 [1–2.3]

 CITe (h)

10.2 [5.0–15.1]

 PP/IAf prior to transplantation (y/n)

42 / 6

  1. Data are given as median [interquartile range]
  2. abody mass index; bPRA: panel reactive antibody; cDD: deceased donor transplantation, LD: living donor transplantation; dMM: mismatches, HLA: human leukocyte antigen; eCIT: cold ischemia time; fPP: plasmapheresis, IA: immunoadsorption